Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis
(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were developed in only a short amount of time and were widely distributed. We conducted this meta-analysis to understand the safety of SARS-CoV-2 vaccines. (2) Methods: We searched the corresponding literature publ...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/596 |
| _version_ | 1797409066898685952 |
|---|---|
| author | Linyi Chen Xianming Cai Tianshuo Zhao Bingfeng Han Mingzhu Xie Jiahao Cui Jiayu Zhang Chao Wang Bei Liu Qingbin Lu Fuqiang Cui |
| author_facet | Linyi Chen Xianming Cai Tianshuo Zhao Bingfeng Han Mingzhu Xie Jiahao Cui Jiayu Zhang Chao Wang Bei Liu Qingbin Lu Fuqiang Cui |
| author_sort | Linyi Chen |
| collection | DOAJ |
| description | (1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were developed in only a short amount of time and were widely distributed. We conducted this meta-analysis to understand the safety of SARS-CoV-2 vaccines. (2) Methods: We searched the corresponding literature published from 1 January 2020 to 20 October 2021. Information of adverse events (AEs) of each selected work was collected. The quality and bias of studies was evaluated, and meta-analysis was carried out by using Stata 17.0. (3) Results: Totally, 11,451 articles were retrieved, and 53 of them were included for analysis. The incidence rate of AEs was 20.05–94.48%. The incidence rate of vascular events increased after viral vector vaccination, while the incidence rate of vascular events decreased after mRNA vaccination. Viral vector vaccine had a higher AE rate compared to mRNA vaccines and inactivated vaccines. In most circumstances, the incidence of AEs was higher in older people, female and after the second dose. The sensitivity of meta-analysis was acceptable; however, the literature was subject to a certain publication bias. (4) Conclusions: The safety of SARS-CoV-2 vaccines was acceptable. The incidence of allergic symptoms and cardiovascular and cerebrovascular symptoms was low. Viral vector vaccine had a higher risk of leading to thrombosis events. The understanding of SARS-CoV-2 vaccine AEs should be enhanced, so as to promote the vaccination. |
| first_indexed | 2024-03-09T04:07:57Z |
| format | Article |
| id | doaj.art-a99a321f0591404ba4d8d654523a707e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T04:07:57Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-a99a321f0591404ba4d8d654523a707e2023-12-03T14:03:44ZengMDPI AGVaccines2076-393X2022-04-0110459610.3390/vaccines10040596Safety of Global SARS-CoV-2 Vaccines, a Meta-AnalysisLinyi Chen0Xianming Cai1Tianshuo Zhao2Bingfeng Han3Mingzhu Xie4Jiahao Cui5Jiayu Zhang6Chao Wang7Bei Liu8Qingbin Lu9Fuqiang Cui10Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, ChinaFaculty of Medicine, Imperial College London, London SW7 2AZ, UKBioinformatics Program, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou 215123, ChinaDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, ChinaDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were developed in only a short amount of time and were widely distributed. We conducted this meta-analysis to understand the safety of SARS-CoV-2 vaccines. (2) Methods: We searched the corresponding literature published from 1 January 2020 to 20 October 2021. Information of adverse events (AEs) of each selected work was collected. The quality and bias of studies was evaluated, and meta-analysis was carried out by using Stata 17.0. (3) Results: Totally, 11,451 articles were retrieved, and 53 of them were included for analysis. The incidence rate of AEs was 20.05–94.48%. The incidence rate of vascular events increased after viral vector vaccination, while the incidence rate of vascular events decreased after mRNA vaccination. Viral vector vaccine had a higher AE rate compared to mRNA vaccines and inactivated vaccines. In most circumstances, the incidence of AEs was higher in older people, female and after the second dose. The sensitivity of meta-analysis was acceptable; however, the literature was subject to a certain publication bias. (4) Conclusions: The safety of SARS-CoV-2 vaccines was acceptable. The incidence of allergic symptoms and cardiovascular and cerebrovascular symptoms was low. Viral vector vaccine had a higher risk of leading to thrombosis events. The understanding of SARS-CoV-2 vaccine AEs should be enhanced, so as to promote the vaccination.https://www.mdpi.com/2076-393X/10/4/596COVID-19vaccinesafetyadverse eventsmeta-analysis |
| spellingShingle | Linyi Chen Xianming Cai Tianshuo Zhao Bingfeng Han Mingzhu Xie Jiahao Cui Jiayu Zhang Chao Wang Bei Liu Qingbin Lu Fuqiang Cui Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis Vaccines COVID-19 vaccine safety adverse events meta-analysis |
| title | Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis |
| title_full | Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis |
| title_fullStr | Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis |
| title_full_unstemmed | Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis |
| title_short | Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis |
| title_sort | safety of global sars cov 2 vaccines a meta analysis |
| topic | COVID-19 vaccine safety adverse events meta-analysis |
| url | https://www.mdpi.com/2076-393X/10/4/596 |
| work_keys_str_mv | AT linyichen safetyofglobalsarscov2vaccinesametaanalysis AT xianmingcai safetyofglobalsarscov2vaccinesametaanalysis AT tianshuozhao safetyofglobalsarscov2vaccinesametaanalysis AT bingfenghan safetyofglobalsarscov2vaccinesametaanalysis AT mingzhuxie safetyofglobalsarscov2vaccinesametaanalysis AT jiahaocui safetyofglobalsarscov2vaccinesametaanalysis AT jiayuzhang safetyofglobalsarscov2vaccinesametaanalysis AT chaowang safetyofglobalsarscov2vaccinesametaanalysis AT beiliu safetyofglobalsarscov2vaccinesametaanalysis AT qingbinlu safetyofglobalsarscov2vaccinesametaanalysis AT fuqiangcui safetyofglobalsarscov2vaccinesametaanalysis |